Crispr Therapeutics Ag (CRSP)
$107.72 0.00 (0.00%)
7:27 EDT CRSP Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 5.05B
PE Ratio -
Volume (Avg. Vol.) 93
Day's Range 107.72 - 107.72
52-Week Range 32.30 - 111.90
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
No matter what risks you think lay ahead for the market (trade war, rate hikes, government shutdown), none of them hurt gene therapy stocks
The future of genetic medicine is bright, but bumpy. But these bumps will provide many opportunities to buy DNA stocks along the way.
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
The biotechnology and pharmaceutical sectors continue to offer great value for investors, and these five Big Pharma stocks stand out from the crowd.
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
Crispr stock is riding a euphoric wave thanks to the biotech firm’s innovations. But what is CRISPR and what are the downsides?
From Market News Video
Investors in CRISPR Therapeutics AG (CRSP) saw new options begin trading this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new December 18th contracts and identified one put and one call contract of particular interest.
From Talk Markets
Navellier RatingsPowered by Portfolio Grader